Radioligand therapy (RLT), as a part of radiopharmaceuticals, delivers high-energy radiation directly to cancer cells by targeting their structural or biochemical mutations.

Avidity Biosciences, a U.S. publicly traded company, announced the latest data from the Phase 1/2 clinical trial FORTITUDE that investigates AOC1020 for treating FSHD.

The improved version of CAR-T therapy, CAR-NK therapy, has recently attracted considerable attention from the academic and pharmaceutical sectors due to its increased tumor-specific targeting and cytotoxicity, cost-effectiveness and easier availability of NK cells, shorter large-scale production cycles, and enhanced efficacy in treating solid tumors.

On June 12, Helsinn Healthcare announced the renewal of its distribution and licensing agreement with Chugai Pharma Europe to promote AKYNZEO® (a combination drug containing netupitant and palonosetron) in the UK and Ireland.

What is the structure of YL202/BNT326, and why is it exhibiting such high toxicity?

The study indicated that Retatrutide (LY3437943), a GLP-1R-related triple receptor agonist currently under clinical development, demonstrated significant efficacy and favorable safety in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD).

Aimovig™ (erenumab) is an injectable human monoclonal antibody (mAb) co-developed and co-marketed by Novartis and Amgen, indicated for the preventive treatment of migraines in adults.

The researchers conducted a prospective docking of extensive compound libraries against the unoptimized AlphaFold2 (AF2) models of the σ2 receptor and the 5-HT2A receptor.

On June 3, the official website of Structure Therapeutics announced top-line data from its 12-week clinical Phase 2a study of the investigational drug GSBR-1290 in obesity.

On May 22, Biogen Inc. and Human Immunology Biosciences (HI-Bio) announced an acquisition agreement. Biogen will acquire HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone payments.

On May 15th, the journal Nature published a research paper titled "GLP-1-directed NMDA receptor antagonism for obesity treatment" by the Novo Nordisk team.

programmed cell death protein 1 (PD-1) inhibitor carrelizumab and Rivoceranib in combination (hereinafter referred to as "Double Ai" combination) received a Complete Response Letter (CRL) from the FDA.